[HTML][HTML] Vaccination in the elderly: the challenge of immune changes with aging
The unprecedented increase of life expectancy challenges society to protect the elderly from
morbidity and mortality making vaccination a crucial mean to safeguard this population …
morbidity and mortality making vaccination a crucial mean to safeguard this population …
Etiology of community-acquired pneumonia in adults: a systematic review
S Shoar, DM Musher - Pneumonia, 2020 - Springer
Background The etiology of community-acquired pneumonia (CAP) has evolved since the
beginning of the antibiotic era. Recent guidelines encourage immediate empiric antibiotic …
beginning of the antibiotic era. Recent guidelines encourage immediate empiric antibiotic …
Pivotal phase 3 randomized clinical trial of the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults aged≥ 18 years
B Essink, C Sabharwal, K Cannon… - Clinical infectious …, 2022 - academic.oup.com
Abstract Background Pneumococcal conjugate vaccines (PCVs) have significantly reduced
pneumococcal disease, but disease from non-PCV serotypes remains. The safety …
pneumococcal disease, but disease from non-PCV serotypes remains. The safety …
Community-acquired pneumonia
E Prina, OT Ranzani, A Torres - The Lancet, 2015 - thelancet.com
Community-acquired pneumonia causes great mortality and morbidity and high costs
worldwide. Empirical selection of antibiotic treatment is the cornerstone of management of …
worldwide. Empirical selection of antibiotic treatment is the cornerstone of management of …
The cGAS-STING pathway in bacterial infection and bacterial immunity
N Liu, X Pang, H Zhang, P Ji - Frontiers in immunology, 2022 - frontiersin.org
Cyclic guanosine monophosphate (GMP)-adenosine monophosphate (AMP)(cGAMP)
synthase (cGAS), along with the adaptor stimulator of interferon genes (STING), are crucial …
synthase (cGAS), along with the adaptor stimulator of interferon genes (STING), are crucial …
Safety, tolerability, and immunogenicity of a 20-valent pneumococcal conjugate vaccine (PCV20) in adults 60 to 64 years of age
D Hurley, C Griffin, M Young Jr, DA Scott… - Clinical Infectious …, 2021 - academic.oup.com
Abstract Background Pneumococcal conjugate vaccines (PCVs) have significantly
decreased pneumococcal disease worldwide; however, expanding serotype coverage may …
decreased pneumococcal disease worldwide; however, expanding serotype coverage may …
Corynebacterium accolens releases antipneumococcal free fatty acids from human nostril and skin surface triacylglycerols
Bacterial interspecies interactions play clinically important roles in shaping microbial
community composition. We observed that Corynebacterium spp. are overrepresented in …
community composition. We observed that Corynebacterium spp. are overrepresented in …
Safety, tolerability, and immunogenicity of a 21-valent pneumococcal conjugate vaccine, V116, in healthy adults: phase 1/2, randomised, double-blind, active …
H Platt, T Omole, J Cardona, NJ Fraser… - The Lancet Infectious …, 2023 - thelancet.com
Background A pneumococcal conjugate vaccine (PCV) specifically focused on serotypes
associated with adult residual disease burden is urgently needed. We aimed to assess …
associated with adult residual disease burden is urgently needed. We aimed to assess …
[HTML][HTML] A phase 3 trial of safety, tolerability, and immunogenicity of V114, 15-valent pneumococcal conjugate vaccine, compared with 13-valent pneumococcal …
HL Platt, JF Cardona, M Haranaka, HI Schwartz… - Vaccine, 2022 - Elsevier
Abstract Background Pneumococcal conjugate vaccines (PCVs) have greatly reduced the
incidence of pneumococcal disease, yet unmet medical need remains due to increased …
incidence of pneumococcal disease, yet unmet medical need remains due to increased …
Effectiveness of 13-valent pneumococcal conjugate vaccine against hospitalization for community-acquired pneumonia in older US adults: a test-negative design
JM McLaughlin, Q Jiang, RE Isturiz… - Clinical Infectious …, 2018 - academic.oup.com
Background Following universal recommendation for use of 13-valent pneumococcal
conjugate vaccine (PCV13) in US adults aged≥ 65 years in September 2014, we conducted …
conjugate vaccine (PCV13) in US adults aged≥ 65 years in September 2014, we conducted …